Hydroxyapatite and cavity prevention

Can hydroxyapatite toothpaste help prevent cavities? A handful of modern randomised trials say specific 10% HA pastes were non-inferior to fluoride controls on defined caries endpoints. That is real clinical signal worth reading carefully. It is not proof that HA has replaced fluoride, or that every “fluoride-free” paste works.

Fluoride still has the larger and longer evidence base — on the order of dozens to nearly a hundred trials in major reviews such as the Cochrane synthesis by Walsh et al. (2019). Keep that asymmetry in view while reading the HA results below. A promising alternative can be true at the same time as “fluoride remains the default evidence heavyweight.”

Remineralisation vs cavity endpoints

Remineralisation studies ask whether early lesions regain mineral under a microscope or hardness test. Cavity-prevention trials ask whether fewer people develop new caries lesions (or related indices such as DMFS) over months in real mouths. They are related but not identical.

A paste can look excellent on artificial lesions and still need clinical caries data. Conversely, a caries non-inferiority win does not map every microscopic mineral pathway. Mechanism background: does hydroxyapatite remineralise teeth?.

Caries is also multifactorial: sugar frequency, plaque control, saliva, fluoride exposure from other sources, and socioeconomic factors all matter. Toothpaste is one intervention inside that system.

Public-health programmes that cut cavity rates in whole populations usually combine water fluoridation or fluoride toothpaste access, education, and clinical care — not a single boutique active. HA enters that conversation as a product-level alternative with growing RCT support, not as a drop-in replacement for decades of fluoride policy. Holding both ideas at once is the honest stance for a site operated by an HA brand.

How to read a non-inferiority trial

These HA caries studies used non-inferiority designs. The question is not “is HA better?” but “is HA unacceptably worse than fluoride within a pre-agreed margin?”

Common features in this literature:

• Margin often set around 20% for the primary difference metric
• Meeting the margin ≠ statistical proof of equality or superiority
• Low overall caries activity can make both arms look successful
• Industry funding does not invalidate a trial, but it belongs in the summary
• “Intention to treat” (ITT) and “per protocol” (PP) analyses can differ slightly; both are worth noting

When a headline says “as effective as fluoride,” check whether the paper actually claimed non-inferiority within Δ. That phrasing gap is where overclaiming starts.

Why margins matter

A 20% margin is relatively generous. It is a design choice that makes sense when you want to show a new option is not dramatically worse than standard care — especially if the new option has other advantages some patients care about (for example, no fluoride ingestion). It is not the same evidentiary bar as proving HA matches fluoride across public-health programmes.

Trial 1 — Schlagenhauf et al., 2019 (orthodontic patients)

Orthodontic brackets create plaque traps. This trial recruited people already at elevated caries risk — a tough test environment.

Results (approximate): ICDAS ≥1 increase in 56.8% (ITT) / 54.7% (PP) with HA vs 60.9% (ITT) / 61.6% (PP) with fluoride; non-inferiority met. Plaque and gingival indices did not differ significantly between arms.

Limitations to keep visible:

• Six months only — shorter than classic multi-year fluoride field trials
• High-risk orthodontic cohort — not automatically generalisable to all adults
• Commercial control formula differed beyond fluoride alone (amine + stannous fluoride system)
• Monthly professional cleaning plus chlorhexidine gel may have suppressed overall caries challenge for everyone in the study
• Product ecosystem is adjacent to Dr. Kurt Wolff / Karex literature — quote the paper’s funding/COI block when publishing detailed critiques

Citation: Journal of Investigative and Clinical Dentistry, 2019; ClinicalTrials.gov NCT02705456.

Trial 2 — Paszynska et al., 2021 (children)

Parents often ask about fluoride-free options because young children swallow paste. This trial is the main modern children’s RCT in the HA caries set.

Funding: Dr. Kurt Wolff GmbH & Co. KG (manufacturer of the test product); universities also listed.

Limitations:

• Industry funding
• Fluoride control at European children’s strength (500 ppm), not adult 1000–1450 ppm — important when people casually say “equal to fluoride”
• High absolute caries incidence in both arms — prevention was incomplete either way
• Primary dentition only

This trial is one reason the kids’ HA toothpaste page exists — and why paediatric fluoride advice still needs a dentist’s input for high-risk children. Avoiding fluorosis risk from swallowed fluoride is a real differentiator; it is not a free pass to ignore caries risk.

Citation: Scientific Reports, 2021;11:2650.

Trial 3 — Paszynska et al., 2023 (adults)

Often cited in briefs as “2022”; the publication year is 2023.

Results (PP): 89.3% HA vs 87.4% fluoride with no DMFS increase; non-inferiority met (upper one-sided 95% CI of the difference well below Δ ≤ 20%).

Funding / COI: Funded by Dr. Kurt Wolff; authors JE, FM, and ESc are employees of Dr. Kurt Wolff.

Limitations:

• Industry funding and employee-authors
• Relatively low caries activity — most subjects had no DMFS increase, which limits assay sensitivity for superiority questions
• 18 months is shorter than classic 2–3 year fluoride field trials
• Adult low-to-moderate risk population

Do not misread 89.3% as “prevented 89.3% of cavities.” It is the share of participants with no DMFS increase. False precision here is a common social-media error.

Citation: Frontiers in Public Health, 2023;11:1199728; NCT04756557. Read the funding and COI blocks in the full text when you cite this trial in detail.

Putting the three trials side by side

A 2024–2025 Journal of Dentistry update pooling these RCTs concludes that clinical non-inferiority evidence is strengthened but still rests on few trials. Sample sizes are typically in the hundreds, not thousands. Durations are months to a year and a half, not multi-year community programmes.

Cross-cutting limitations (apply to almost all HA caries RCTs)

1. Sample sizes — hundreds, not thousands
2. Duration — 6–18 months vs multi-year fluoride field trials
3. Industry funding — concentrated (notably Dr. Kurt Wolff / Karex line; historically Sangi for Japanese products)
4. Non-inferiority margins — often 20%; “not worse within 20%” ≠ “as proven as fluoride”
5. Product heterogeneity — these trials used microcrystalline 10% HA; nano grades, zinc-carbonate systems, and undisclosed blends are not automatically covered
6. Author networks overlapping manufacturers appear in related systematic reviews — disclose when summarising

What these trials do not show

• Superiority of HA over fluoride for caries
• That nano-HA was tested in these pivotal RCTs
• That all fluoride-free toothpastes work — many lack this level of data (does fluoride-free toothpaste work?)
• FDA anticaries approval or an ADA Seal for HA cavity protection
• Independent, multi-year, multi-thousand-participant field trials on the fluoride scale

Fluoride context (required honesty)

Walsh et al.’s Cochrane review (2019) synthesised 96 studies on fluoride toothpaste concentrations. Network meta-analysis in that review supports caries reductions for common fluoride concentration bands versus non-fluoride controls. Public-health dentistry still centres fluoride for good reason: volume, duration, and independent synthesis.

In the United States:

• Fluoride is the OTC monograph anticaries active (Monograph M021)
• HA pastes are generally sold as cosmetics
• ADA guidance: cavity-protection Seal toothpastes must contain fluoride

A full even-handed comparison lives at hydroxyapatite vs fluoride. Japan’s longer market history and 1993 anti-caries recognition for a proprietary HA pathway are covered in the Japanese history article — historical adoption is not the same as matching Cochrane-scale evidence.

Who might still choose an HA paste after reading this

Reasonable motivations include:

• Preference for a fluoride-free routine after understanding evidence gaps
• Dentin hypersensitivity as a primary complaint (stronger HA clinical chapter than caries alone)
• Caregiver concern about fluorosis / paste swallowing in young children — discussed with a dentist, risk-dependent
• Alignment with biomimetic product philosophy

Unreasonable motivations include:

• Belief that HA is proven superior to fluoride for cavities
• Belief that any natural fluoride-free paste inherits these RCT results
• Using web summaries to override a dentist’s plan for high-risk decay

Switching toothpaste is easy; changing risk is not. If someone has multiple new lesions each year, the priority is a full caries-management plan — diet diary, saliva assessment, professional fluoride varnish or high-fluoride paste when indicated, restorative care for cavitated lesions — with HA or fluoride toothpaste as one daily layer inside that plan.

Concentration note

These caries RCTs predominantly tested 10% microcrystalline HA. Remineralisation in situ can look similar at 5% and 10% nHA (Najibfard 2011), but if your question is “what did the cavity trials use?”, the answer is mostly 10%. More detail: 5% vs 10%.

Matching a studied concentration does not automatically match a studied formula. Abrasives, surfactants, xylitol, zinc salts, and flavour systems differ across brands. Non-inferiority for one 10% microcrystalline paste is evidence about that intervention class — not a certificate for every tube that prints “hydroxyapatite” in small type. Prefer products that disclose percentage and particle class, then read claims against the trial designs above.

ICDAS, DMFS, and why endpoints confuse readers

ICDAS (International Caries Detection and Assessment System) scores enamel and dentin changes visually. An ICDAS ≥1 threshold catches early enamel caries — useful in orthodontic trials where white-spot risk is high, but not identical to “a cavity that needs a filling.”

DMFS counts decayed, missing (due to caries), and filled tooth surfaces. “No DMFS increase” means the person’s caries experience score did not rise during follow-up. In a low-caries adult sample, most people in both arms may show no increase — which helps non-inferiority but limits claims about dramatic prevention percentages.

When influencers turn “89.3% had no DMFS increase” into “prevents 89% of cavities,” they are misreading the endpoint. Precision about endpoints is part of evidence literacy.

How these trials relate to remineralisation lab work

Huang (2009), Najibfard (2011), and Amaechi (2019/2022) support the mechanistic claim that HA can remineralise early lesions. The Schlagenhauf and Paszynska RCTs ask a harder public question: in real patients using a full toothpaste formula twice or three times daily, do caries indices stay within a non-inferiority band versus fluoride?

Positive answers at both levels are encouraging. They still leave open:

• Head-to-head nano vs micro caries RCTs
• Multi-year independent trials at public-health scale
• Performance in very high-risk medically complex patients without the supportive co-interventions seen in some protocols

Industry funding without conspiracy thinking

Dr. Kurt Wolff funding appears repeatedly in this trial cluster. Several co-authors of the adult trial are company employees. Meyer and Enax appear across modes-of-action reviews and meta-analyses in the wider HA literature.

That pattern is a reason for transparent citation, not automatic dismissal. Industry funds many dental-product trials because public funders do not prioritise every toothpaste active equally. Readers should still prefer full-text funding statements over press-release summaries. Readers deserve:

1. Named funders
2. Named employee-authors when relevant
3. Fluoride Cochrane-scale context in the same article
4. Clear non-inferiority language instead of “proven equal”

Japan’s 1980–1993 history shows long market use and a domestic anti-caries recognition pathway for a proprietary HA. That history supports familiarity and cumulative exposure — it does not replace the need for modern randomised evidence when advising patients in other regulatory systems. Keep both timelines on the desk.

Practical reading for patients

• If you want a fluoride-free option with clinical caries data, look for products aligned with the 10% HA concentrations studied — and understand which particle form was tested.
• If you are high risk, orthodontic, or caring for a child with decay history, get personalised advice rather than relying on web summaries alone.
• Remineralisation mechanism questions: remineralisation evidence.
• Safety and swallowing context: is HA toothpaste safe? and kids.
• Shopping and label literacy: buyer’s guide and 5% vs 10%.
• Routine habits that affect mineral pastes: how to use hydroxyapatite toothpaste.

If your dentist recommends continuing fluoride, that advice is aligned with the larger evidence base. If you and your dentist choose an HA paste for a specific reason (sensitivity, fluorosis concerns, preference), you can do so with eyes open about what the RCTs did and did not prove.